Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Research context
Healius Limited appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Healius Limited is currently in a long term uptrend where the price is trading 18.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Healius Limited's total revenue sank by 0.0% to $473M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $33M since the same quarter in the previous year.
Finally, its free cash flow grew by 149.2% to $126M since the same quarter in the previous year.
Based on the above factors, Healius Limited gets an overall score of 3/5.